Welcome to our dedicated page for Virax Biolabs Group SEC filings (Ticker: VRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Virax Biolabs Group Limited filings document a foreign private issuer developing immunology research and diagnostic technologies, including disclosures tied to the ViraxImmune platform and immune-profiling strategy. Form 6-K reports include shareholder letters, investor presentation exhibits, clinical and commercial framework updates, and statements on the company’s ordinary shares.
The filing record also covers capital-structure matters such as private placements, pre-funded warrants, preferred investment options and ordinary-share issuance. Governance disclosures include annual general meeting notices, proxy materials, shareholder voting and quorum matters, auditor ratification, director elections, board committee appointments, equity incentive plans, and amendments to memorandum and articles of association.
Virax Biolabs Group Limited reported early pilot performance data for ViraxImmune™, a blood-based test in development for Long COVID, ME/CFS and related post-acute infection syndromes. In the pilot dataset, the test showed measurable separation between PAIS patients and healthy controls, with 88% specificity and 92% positive predictive value.
ViraxImmune™ has been evaluated in more than 120 subjects in an ongoing UK clinical study. Virax plans a larger clinical validation using samples from 300 additional participants, with analysis expected to begin in Q4 2026 and results expected in Q1 2027, supporting a planned U.S. market-entry via a PAIS-focused Laboratory Developed Test followed by broader in vitro diagnostic development. Virax estimates up to 21 million U.S. adults may be living with Long COVID and related PAIS conditions, with about 2.5 million new cases each year.
Virax Biolabs Group Limited is calling an extraordinary general meeting on June 5, 2026 to seek shareholder approval for a significant share consolidation and related charter changes. The Board proposes consolidating authorized, issued and outstanding ordinary shares at a ratio between 10‑for‑1 and 30‑for‑1, with the exact ratio to be set later and effective on or before July 11, 2026, and fractional entitlements rounded up to the nearest whole share.
The consolidation is intended to help Virax regain compliance with Nasdaq’s Minimum Bid Price Rule, which requires a minimum closing bid of $1.00 per share after the company received deficiency notices and an extension to July 11, 2026. Shareholders will also vote on adopting a fourth amended and restated memorandum and articles of association reflecting the consolidation, plus an adjournment proposal that would allow additional time to solicit proxies if needed. The record date for voting is May 18, 2026, with one vote per ordinary share and a quorum requirement of at least one‑third of voting shares.
Armistice Capital, LLC and Steven Boyd filed an amendment to Schedule 13G disclosing beneficial ownership of 1,000,239 ordinary shares of Virax Biolabs Group Limited, representing 4.99% of the class.
The filing states Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., which directly holds the shares, and that Armistice exercises shared voting and dispositive power over the reported securities. The amendment is signed by Steven Boyd on 05/15/2026.
Virax Biolabs Group Limited filed a Form 6-K highlighting a shareholder letter and updated investor presentation that set out its current strategy and key milestones over the next 90–180 days. The company is focusing on its in-development ViraxImmune™ T cell immune‑profiling platform for post-acute infection syndromes, initially via a U.S. Laboratory Developed Test pathway, with broader in vitro diagnostic development to follow.
Management notes UK PAIS studies are fully recruited, an initial FDA pre-submission meeting is complete, U.S. clinical validation planning with Emory University is under way, and Virax has achieved ISO 13485 and ISO 9001 certification. The letter states an expected unaudited cash balance of approximately $6.4 million at March 31, 2026 versus a market capitalisation of about $2.6 million based on 19,923,432 shares, and emphasizes disciplined execution toward validation and U.S. market entry.
Virax Biolabs Group Limited reports that all 12,500,000 pre-funded warrants issued in a prior private placement have now been exercised. That private placement raised gross proceeds of $5,000,000 through pre-funded warrants and preferred investment options sold at $0.3999 per unit. Following the exercises, the company’s ordinary shares outstanding total 19,923,432 as of April 10, 2026.
Virax Biolabs Group Ltd director Nelson M. Haight reported his initial beneficial ownership of stock options in the company. The holdings include options over 2,000 Ordinary Shares with a $15.40 exercise price expiring on November 17, 2032, granted under the 2023 Equity Incentive Plan.
He also holds options over 10,000 Ordinary Shares with a $6.00 exercise price expiring on April 18, 2033, 10,000 options at $0.68 expiring on April 18, 2034, and 10,000 options at $0.88 expiring on April 8, 2035. Footnotes state these options vest in scheduled halves or thirds on specified future dates, becoming exercisable as they vest.
Virax Biolabs Group Ltd director and Chief Operating Officer Nigel William McCracken filed an initial Form 3 disclosing stock option holdings. He holds options over 20,000 ordinary shares at an exercise price of $3.6000 expiring on September 1, 2033, 50,000 shares at $0.6800 expiring on April 18, 2034, and two grants over 20,584 and 29,416 shares at $0.8800 expiring on April 8, 2035. Footnotes state these options were granted under the company’s 2023 and 2024 Equity Incentive Plans and vest in equal thirds over three years, with vested portions becoming exercisable upon vesting.
Virax Biolabs Group Limited reported the results of its 2025 adjourned annual meeting of shareholders. With a quorum deemed present at the reconvened meeting, shareholders approved five key items. They ratified Reliant CPAs PC as auditor for the year ending March 31, 2026 and elected all five director nominees. Shareholders also approved a share consolidation of ordinary shares on a one-for-ten to one-for-fifteen basis, increasing par value per share accordingly. They adopted a new fourth amended and restated memorandum and articles of association to reflect revised authorized share capital, effective with the consolidation. In addition, shareholders approved a 2026 Equity Incentive Plan and UK Sub-Plan reserving 2,000,000 ordinary shares for issuance.
Virax Biolabs Group Ltd Chief Executive Officer Foster James Alexander Cunliffe filed an initial statement of beneficial ownership, showing 287,987 Ordinary Shares held directly plus multiple stock option awards over additional Ordinary Shares. These options carry exercise prices ranging from $50.00 down to $0.68 per share and expire between 2032 and 2035. Footnotes explain that the grants were made under the company’s 2023 and 2024 equity incentive plans, with vesting schedules that generally occur in equal annual installments over three years, becoming exercisable as they vest.
Virax Biolabs Group Ltd director Norton Evan Michael filed an initial statement of beneficial ownership, reporting stock option holdings over the company’s ordinary shares. He holds options for 2,000 shares at an exercise price of $6.0000 expiring on July 20, 2032, and 10,000 shares at $6.0000 expiring on April 18, 2033. He also holds 10,000 options at $0.6800 expiring on April 18, 2034 and 10,000 options at $0.8800 expiring on April 8, 2035. Footnotes state these options were granted between July 20, 2022 and April 8, 2025 under the company’s equity incentive plans, with vesting in halves or thirds and becoming exercisable upon vesting.